 |
|
|
| |
Efficacy, safety and pharmacokinetics of 12 weeks of simeprevir in combination with TMC647055 and ritonavir with or without ribavirin in genotype 1 hepatitis C virus-infected patients
|
| |
| |
Reported by Jules Levin
APASL 2015
24th Conference of the Asian Pacific Association for the Study of the Liver (APASL), 12-15 March 2015, Istanbul, Turkey
Bourgeois S1, Van Vlierberghe H2, Moreno C3, Orlent H4, Vijgen L5, Kakuda TN6, Hoeben E7, Kirsila T5, Vandebosch A7, Jacquemyn B5, Van Remoortere P6, Verloes R7
1Department of Gastroenterology & Hepatology, ZNA Antwerp, Antwerp, Belgium; 2Department of Hepatology and Gastroenterology, Universitair Ziekenhuis Gent, Ghent, Belgium; 3ULB Hopital Erasme, Universite Libre de Bruxelles, Brussels, Belgium; 4Department of Gastroenterology and Hepatology, AZ Sint-Jan AV Hospital, Bruges, Belgium; 5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Janssen Pharmaceuticals LLC, Titusville, NJ, USA; 7Janssen Research & Development BVBA, Beerse, Belgium
|
| |
|
|
|
|
|
